Literature DB >> 14614052

Aberrant intranuclear localization of biotin, biotin-binding enzymes, and beta-catenin in pregnancy-related endometrium and morule-associated neoplastic lesions.

Ayako Gamachi1, Kenji Kashima, Tsutomu Daa, Yukio Nakatani, Masahiko Tsujimoto, Shigeo Yokoyama.   

Abstract

Biotin-rich intranuclear inclusions, also known as optically clear nuclei, have been observed in various neoplastic and non-neoplastic lesions. They look like nuclei of herpesvirus-infected cells and cause a false-positive immunohistochemical result by avidin-biotin-complex (ABC) method. In the literature, all types of neoplastic lesions with intranuclear inclusions, with one exception, have been characteristically associated with squamoid structures known as morules. By contrast, all reported non-neoplastic lesions with such inclusions lacked morules and were confined to pregnancy-related endometrium. In the present study, adding unreported types of morule-associated neoplastic lesions, we investigated the distribution of biotin, biotin-binding enzymes, and beta-catenin in these lesions by immunohistochemical staining. We detected the intranuclear localization of biotin and of two mitochondrial biotin-binding enzymes (pyruvic acid carboxylase and propionyl CoA carboxylase) in all lesions examined, regardless of whether they were neoplastic or non-neoplastic and irrespective of the presence or absence of morules. The intranuclear localization of beta-catenin was detected in all neoplastic lesions with morules and in ovarian endometrioid adenocarcinoma without morules, but not in non-neoplastic endometrial lesions. These results suggest the following conclusions: (1) lesions with biotin-rich intranuclear inclusions can be classified as non-neoplastic/pregnancy-related endometrial and as neoplastic/pregnancy-unrelated or morular category; (2) the intranuclear biotin in both types of lesion is found in conjunction with biotin-binding enzymes. However, the role of beta-catenin in morule-associated neoplastic lesions, the relationship between beta-catenin and biotin/biotin-binding enzymes, and the mechanism of migration of biotin and biotin-binding enzymes from the cytoplasm to the nucleus remain unclear.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614052     DOI: 10.1097/01.MP.0000092953.20717.48

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  5 in total

1.  Protein inhibitor of activated STAT1 interacts with and up-regulates activities of the pro-proliferative transcription factor Krüppel-like factor 5.

Authors:  James X Du; C Chris Yun; Agnieszka Bialkowska; Vincent W Yang
Journal:  J Biol Chem       Date:  2006-12-18       Impact factor: 5.157

2.  Aberrant expression of an "intestinal marker" Cdx2 in pyloric gland adenoma of the gallbladder.

Authors:  Yoji Wani; Kenji Notohara; Masayoshi Fujisawa
Journal:  Virchows Arch       Date:  2008-10-09       Impact factor: 4.064

Review 3.  beta-Catenin expression in thyroid follicular lesions: potential role in nuclear envelope changes in papillary carcinomas.

Authors:  S Rezk; R K Brynes; V Nelson; M Thein; N Patwardhan; A Fischer; A Khan
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

4.  Biotin-rich intranuclear inclusions in morule-lacking adenocarcinoma of the gallbladder: a new category of "neoplastic/non-morular" lesions.

Authors:  Yasuhiko Kimura; Kenji Kashima; Tsutomu Daa; Yoshiyuki Kondo; Kazuhiro Yada; Atsushi Sasaki; Toshifumi Matsumoto; Seigo Kitano; Nobuhiro Kubo; Shigeo Yokoyama
Journal:  Virchows Arch       Date:  2005-01-13       Impact factor: 4.064

5.  Intracholecystic tubular non-mucinous neoplasm (ICTN) of the gallbladder: a clinicopathologically distinct, invasion-resistant entity.

Authors:  Burcin Pehlivanoglu; Serdar Balci; Olca Basturk; Pelin Bagci; Ipek Erbarut Seven; Bahar Memis; Nevra Dursun; Kee-Taek Jang; Burcu Saka; Nobuyuki Ohike; Takuma Tajiri; Juan Carlos Roa; Juan M Sarmiento; Michelle D Reid; Volkan Adsay
Journal:  Virchows Arch       Date:  2020-07-20       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.